| Followers | 19 |
| Posts | 6633 |
| Boards Moderated | 1 |
| Alias Born | 05/23/2019 |
Friday, May 15, 2026 6:18:06 AM
WQLF SAYS: GR8 NEWS and GR8 Quarterly Report. NO CASH BURN for Q1 2026. Cash remaining $300,000 not including the Cash for Equity Swap from Streeterville in Q2 of $99,614.04. There will be more shares added to the Outstanding. The positive is that the company will not have to borrow any more funds from the Lender. We have enough cash on hand to survive through 2026 as long as we continue to operate as we did in Q1 2026. Thanks to the Management of CV SCIENCES we are NOW on the path of Complete Survival. The TROLL 🧌 🧌 with numerous NICS is still irrelevant. Just Noise 😭. From this point on, it would be WISE 🦉 to buy the shares T this Price. Have Mercy WQLF ahoooooo
Ai Generated:
In Q1 2026, CV Sciences achieved a significant turnaround by reporting positive operating cash flow, effectively eliminating operational cash burn for the period. The company showed strong resilience, managing a modest operating loss and narrowing its Adjusted EBITDA loss.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1510964/000119312526151228/cvsi-20260406.htm
Ai Generated:
In Q1 2026, CV Sciences achieved a significant turnaround by reporting positive operating cash flow, effectively eliminating operational cash burn for the period. The company showed strong resilience, managing a modest operating loss and narrowing its Adjusted EBITDA loss.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1510964/000119312526151228/cvsi-20260406.htm
Bullish
Recent CVSI News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:10:09 PM
- CV Sciences, Inc. Reports First Quarter-End 2026 Financial Results • ACCESS Newswire • 05/14/2026 08:00:00 PM
- CV Sciences, Inc. To Announce First Quarter 2026 Results On May 14, 2026 • ACCESS Newswire • 05/12/2026 10:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2026 08:04:10 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/26/2026 09:14:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 08:06:03 PM
- CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results • ACCESS Newswire • 03/26/2026 08:00:00 PM
- CV Sciences, Inc. To Announce Year End and Fourth Quarter 2025 Results On March 26, 2026 • ACCESS Newswire • 03/24/2026 09:00:00 PM
- CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth • ACCESS Newswire • 03/10/2026 09:00:00 PM
- CV Sciences Launches EMPOWR: A Plant-Based Protein + Creatine Formula Designed for Total Wellness • ACCESS Newswire • 02/26/2026 01:30:00 PM
- CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD • ACCESS Newswire • 12/23/2025 12:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 10:19:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:04:08 PM
- CV Sciences, Inc. Reports Third Quarter 2025 Financial Results • ACCESS Newswire • 11/13/2025 09:00:00 PM
- CV Sciences, Inc. to Announce Third Quarter 2025 Results on November 13, 2025 • ACCESS Newswire • 11/10/2025 11:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2025 09:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2025 08:24:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 09:23:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2025 08:01:09 PM
